Radio and PodcastLive Radio & Podcasts

Search Radio and Podcast

Podcasts›Breaking Biotech›106 - Bright Spot Among CRISPR in Caribou Biosci. 2022 Biotech Trends to Watch!

Science & Medicine

106 - Bright Spot Among CRISPR in Caribou Biosci. 2022 Biotech Trends to Watch!

Breaking Biotech by Matthew Lepoire

Jan 9, 202200:42:53Science & Medicine

CRISPR is an exciting space, with a number of companies finally sharing early clinical data in 2021. NTLA benefitted the most from this by doubling in valuation after data release, while the other CRISPR companies contin...

Related Episodes

Continue listening to more episodes from Breaking Biotech.

113 - Vaxxinity Takes on Neurodegenerative Diseases with Vaccines - Potential Short Opportunity?

May 8, 2022 - 00:45:36

Video Sponsor - In this episode, I go through a company called Vaxxinity, who are trying to develop vacci...

112 - Biotech Updates - $BTAI $TGTX $CRIS $CKPT $KPTI $SRRA

Apr 21, 2022 - 00:43:59

In this episode, I take a look at 6 different biotechs and talk about recent updates in each one. Here is...

111 - Achieve Life Sciences Phase 3 Readout Imminent! Interview with CEO John Bencich

Apr 1, 2022 - 00:28:19

Achieve Life Sciences is developing Cytisinicline for the treatment of smoking cessation. The drug has be...

110 - Kodiac Sciences FALLS on Negative Wet AMD Readout! Buying Opportunity or Falling Knife??

Mar 5, 2022 - 00:33:19

Kodiac Sciences is developing KSI-301 for a number of proliferative endothelial retinal disorders. Their...

109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results

Feb 22, 2022 - 00:33:42

Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBC...

108 - NASH Companies to Watch in 2022! Madrigal Pharma Announces Positive Data in NAFLD

Feb 7, 2022 - 00:37:28

The NASH space has seen some setbacks in the last couple years, but a few players continue to make nice p...

107 - CymaBay Sets to Massively Improve Outcomes in PBC Patients Interview with CEO Sujal Shah

Jan 29, 2022 - 00:35:09

CymaBay Therapeutics is developing Seladelpar for the treatment of Primary Biliary Cholangitis (PBC). PBC...

105 - Neurodegenerative Disease Recap! ALXO and LGVN updates plus Breaking Breaking 2021 Top Trades

Jan 3, 2022 - 00:41:29

ALXO announces new HR-MDS data that disappoints! I talk about the comparison to Magrolimab data and why I...